IMA950 in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) exhibited safety, tolerance, and immunogenicity in HLA-A*02-positive glioblastoma patients (N=45) in phase 1 clinical trials (intradermally). Here, CSF2 is linked to glioblastoma.